BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 18563785)

  • 1. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.
    Lindholm E; Brevinge H; Haglind E
    Br J Surg; 2008 Aug; 95(8):1029-36. PubMed ID: 18563785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
    Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
    J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early detection of colorectal cancer with faecal occult blood test screening.
    Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H
    Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
    Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
    Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study.
    Faivre J; Tazi MA; El Mrini T; Lejeune C; Benhamiche AM; Dassonville F
    Br J Cancer; 1999 Feb; 79(3-4):680-3. PubMed ID: 10027349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Randomized controlled trial of sequence mass screening program for colorectal cancer].
    Liu X; Zheng S; Chen K; Ma X; Zhou L; Yu H; Yao K; Chen K; Cai S; Zhang S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Dec; 21(6):430-3. PubMed ID: 11860828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds.
    Kronborg O; Jørgensen OD; Fenger C; Rasmussen M
    Scand J Gastroenterol; 2004 Sep; 39(9):846-51. PubMed ID: 15513382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 25-year follow-up of a population screened with faecal occult blood test in Finland.
    Malila N; Hakama M; Pukkala E
    Acta Oncol; 2007; 46(8):1103-6. PubMed ID: 17851857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.
    Mandel JS; Bond JH; Church TR; Snover DC; Bradley GM; Schuman LM; Ederer F
    N Engl J Med; 1993 May; 328(19):1365-71. PubMed ID: 8474513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: a prospective cohort study in Japan.
    Lee KJ; Inoue M; Otani T; Iwasaki M; Sasazuki S; Tsugane S;
    Cancer Detect Prev; 2007; 31(1):3-11. PubMed ID: 17289293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
    Musil D; Tillich J
    Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations on population screening for colorectal cancer in New Zealand. Members of the National Health Committee Working Party on Population Screening for Colorectal Cancer.
    N Z Med J; 1999 Jan; 112(1080):4-6. PubMed ID: 10073156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population-based estimate of the extent of colorectal cancer screening in Ontario.
    Rabeneck L; Paszat LF
    Am J Gastroenterol; 2004 Jun; 99(6):1141-4. PubMed ID: 15180738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mass screening for colorectal cancer].
    Faivre J; Tazi MA; Launoy G
    Rev Epidemiol Sante Publique; 1996; 44 Suppl 1():S7-14. PubMed ID: 8935859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial.
    Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Church T; Yurgalevitch S; Austin JH; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Jul; 97(13):989-97. PubMed ID: 15998952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic yield in a biennial Hemoccult-II screening program compared to a once-only screening with flexible sigmoidoscopy and Hemoccult-II.
    Rasmussen M; Fenger C; Kronborg O
    Scand J Gastroenterol; 2003 Jan; 38(1):114-8. PubMed ID: 12608473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening.
    Berry DP; Clarke P; Hardcastle JD; Vellacott KD
    Br J Surg; 1997 Sep; 84(9):1274-6. PubMed ID: 9313712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of patients diagnosed with colorectal cancer through a television-advertised screening program.
    Slusser SO; Liberski SM; McGarrity TJ
    Am J Gastroenterol; 1996 Aug; 91(8):1563-6. PubMed ID: 8759662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.